Editas Medicine presents EDIT-401 data showing over 90% mean LDL-C reduction in nonhuman primates
EDIT•Editas Medicine reported that a single EDIT-401 dose produced greater than 90% mean LDL-C reduction in nonhuman primates, sustained for approximately 10 months. The company expects initial Strive study safety and tolerability data in the first quarter of 2027 and says its cash runway extends into the second half of 2028.
1. Preclinical findings
Editas Medicine reported greater than 90% mean LDL-C reduction after a single EDIT-401 dose in nonhuman primates, sustained through approximately 10 months. Preclinical safety findings included transient liver enzyme elevations, with no bilirubin elevations or liver histopathological changes. Initial safety and tolerability data from the Strive study are expected in the first quarter of 2027; Part 1 enrollment completion and topline safety and efficacy results are targeted for the second half of 2027. The company said its cash runway extends into the second half of 2028.
